Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Exp Neurol. 2017 Feb 16;292:35–45. doi: 10.1016/j.expneurol.2017.02.012

Figure 4. Qualitative effect of FNCS1 antagonism on inflammatory demyelination in murine SAPP.

Figure 4

Representative digital indirect fluorescent photomicrographs from the sciatic nerves of SAPP-affected mice 30 days after treatment initiation show the normal honeycomb appearance of myelinated axons with S100β staining [green]) following FNCS1 treatment (a) in contrast to multiple foci of inflammatory cells (blue) associated with endoneurial architecture disruption (altered honeycomb appearance) consistent with demyelination in FNCS1C peptide-treated mice (b). Normal axonal density (NF-H staining [red]) with rare mononuclear cells is shown in a FNCS1 peptide-treated mouse (c), in contrast to the intense diffuse inflammatory infiltrate associated with focal axonal loss in a FNCS1C peptide-treated mouse (d). The variability in demyelination and focal axonal loss associated with endoneurial mononuclear cell infiltration following IVIg- (e–h) and 6αMP- (i– l) treated SAPP-affected mice is also shown. These images were obtained from serial sections containing CD45+ leukocytes. Scale bars = 50 μm